Clostridium difficile infection (CDI) has increased in incidence and severity worldwide, causing direct costs estimated to range from US $3.2 billion to $4.8 billion. The aim of this study was to investigate and identify factors that predict recurrence of CDI.
Methods
This was a retrospective case-control study between 2007 and 2013 on patients admitted with CDI. Recurrent CDI is defined as a new episode of diarrhea within 90 days confirmed by a positive stool C. difficile toxin assay or polymerase chain reaction, after resolution of the initial CDI episode for at least 10 days and after discontinuation of the CDI therapy.
Results
Three thousand twenty patients were diagnosed with CDI between January 2007 and December 2013. Two hundred nine of 2019 patients in the study had a recurrence of CDI within 90 days of the end of the initial CDI episode (10.3%). Multivariate analysis showed that most of the recurrences occurred in patients with comorbidities, particularly chronic kidney disease (odds ratio, 1.3; 95% confidence interval [CI], 1.0–2.4; P = 0.039). In addition, a higher percentage of patients in the recurrence group were prescribed proton-pump inhibitors (odds ratio, 1.65; 95% CI, 1.0–1.7; P = 0.002) and steroids (odds ratio, 1.65; 95% CI, 1.0–1.5; P = 0.047).
Conclusions
Our data suggest that the use of glucocorticoids, use of proton-pump inhibitors, and having end-stage renal disease are significant risk factors associated with recurrent CDI.
BartlettJG, ChangTW, GurwithM, . Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978; 298: 531–534.
2.
Motzkus-FeagansCA, PakyzA, PolkR, . Statin use and the risk of Clostridium difficile in academic medical centres. Gut. 2012; 61: 1538–1542.
3.
O'BrienJA, LahueBJ, CaroJJ, . The emerging infectious challenge of Clostridium difficile–associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007; 28: 1219–1227.
4.
FerradaP, VelopulosCG, SultanS, . Timing and type of surgical treatment of Clostridium difficile–associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2014; 76: 1484–1493.
5.
SurawiczCM, BrandtLJ, BinionDG, . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108: 478–498; quiz 499.
ZereyM, PatonBL, LincourtAE, . The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt). 2007; 8: 557–566.
8.
ParkSW, ChoiAR, LeeHJ, . The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther. 2013; 38: 619–627.
9.
KyneL, WarnyM, QamarA, . Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001; 357: 189–193.
10.
LooVG, BourgaultAM, PoirierL, . Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011; 365: 1693–1703.
11.
HuMY, KatcharK, KyneL, . Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009; 136: 1206–1214.
12.
OlsonMM, ShanholtzerCJ, LeeJTJr, . Ten years of prospective Clostridium difficile–associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol. 1994; 15: 371–381.
13.
BartlettJG.Narrative review: the new epidemic of Clostridium difficile–associated enteric disease. Ann Intern Med. 2006; 145: 758–764.
14.
GareyKW, SethiS, YadavY, . Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008; 70: 298–304.
15.
Rodriguez-PardoD, AlmiranteB, BartolomeRM, . Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol. 2013; 51: 1465–1473.
16.
McFarlandLV, SurawiczCM, RubinM, . Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999; 20: 43–50.
17.
MoshkowitzM, Ben-BaruchE, KlineZ, . Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis. 2007; 9: 173–177.
18.
ZilberbergMD, ReskeK, OlsenM, . Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med. 2014; 9: 418–423.
19.
DubberkeER, ReskeKA, OlsenMA, . Evaluation of Clostridium difficile–associated disease pressure as a risk factor for C. difficile–associated disease. Arch Intern Med. 2007; 167: 1092–1097.
20.
PepinJ, RouthierS, GagnonS, . Management and outcomes of a first recurrence of Clostridium difficile–associated disease in Quebec, Canada. Clin Infect Dis. 2006; 42: 758–764.
21.
GarnerJS.Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1996; 17: 53–80.
EddiR, MalikMN, ShakovR, . Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton). 2010; 15: 471–475.
24.
YousufK, SaklayenMG, MarkertRJ, . Clostridium difficile–associated diarrhea and chronic renal insufficiency. South Med J. 2002; 95: 681–683.
25.
KeddisMT, KhannaS, NoheriaA, . Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012; 87: 1046–1053.
26.
StuckAE, MinderCE, FreyFJ.Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989; 11: 954–963.
27.
MorrisonRH, HallNS, SaidM, . Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011; 53: 1173–1178.
28.
DasR, FeuerstadtP, BrandtLJ.Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile–associated disease. Am J Gastroenterol. 2010; 105: 2040–2049.
29.
DeshpandeA, PantC, PasupuletiV, . Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10: 225–233.
30.
KwokCS, ArthurAK, AnibuezeCI, . Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012; 107: 1011–1019.
31.
BarlettaJF, El-IbiarySY, DavisLE, . Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013; 88: 1085–1090.
32.
KimYG, GrahamDY, JangBI.Proton pump inhibitor use and recurrent Clostridium difficile–associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol. 2012; 46: 397–400.
33.
FreedbergDE, SalmasianH, FriedmanC, . Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection Among Inpatients. American Journal of Gastroenterology. 2013; 108: 1794–1801.
34.
ShahS, LewisA, LeopoldD, . Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000; 93: 175–181.
35.
Zedtwitz-LiebensteinK, WenischC, PatrutaS, . Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002; 30: 1118–1122.
36.
YoshidaN, YoshikawaT, TanakaY, . A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000; 14 (Suppl 1): 74–81.
37.
WilliamsC.Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001; 15: 511–521.
38.
RogersMA, GreeneMT, YoungVB, . Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med. 2013; 11: 121.
39.
DaltonSO, LaursenTM, RossL, . Risk for hospitalization with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. J Clin Oncol. 2009; 27: 1440–1445.
40.
McFarlandLV.Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998; 16: 292–307.
41.
TeasleyDG, GerdingDN, OlsonMM, . Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile–associated diarrhoea and colitis. Lancet. 1983; 2: 1043–1046.
42.
PepinJ, AlaryME, ValiquetteL, . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40: 1591–1597.
43.
MusherDM, AslamS, LoganN, . Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40: 1586–1590.
44.
FernandezA, AnandG, FriedenbergF.Factors associated with failure of metronidazole in Clostridium difficile–associated disease. J Clin Gastroenterol. 2004; 38: 414–418.
45.
JungKS, ParkJJ, ChonYE, . Risk factors for treatment failure and recurrence after metronidazole treatment for Clostridium difficile–associated diarrhea. Gut Liver. 2010; 4: 332–337.
